SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-22-084520
Filing Date
2022-03-25
Accepted
2022-03-25 07:01:00
Documents
6
Period of Report
2022-05-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A d320930ddef14a.htm DEF 14A 486232
2 GRAPHIC g320930g01o95.jpg GRAPHIC 200060
3 GRAPHIC g320930g02o96.jpg GRAPHIC 188482
4 GRAPHIC g320930g17k02.jpg GRAPHIC 21756
5 GRAPHIC g320930g17k31.jpg GRAPHIC 59001
6 GRAPHIC g320930g17k32.jpg GRAPHIC 60886
  Complete submission text file 0001193125-22-084520.txt   1215578
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: DEF 14A | Act: 34 | File No.: 001-39398 | Film No.: 22768199
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences